MedTrace Logo

Early Transcranial Doppler Goal Directed Therapy After Cardiac Arrest: a Pilot Study

NCT04000334 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-05-02

No results posted yet for this study

Summary

Hypoxic-ischaemic brain injury (HIBI) is the main cause of death in patients who are comatose after resuscitation from cardiac arrest. Current guidelines recommend to target a mean arterial pressure (MAP) above 65 mmHg to achieve an adequate organ perfusion. Moreover, after cardiac arrest, cerebral autoregulation is dysregulated and cerebral blood flow (CBF) depends on the MAP. A higher blood pressure target could improve cerebral perfusion and HIBI. Transcranial Doppler (TCD) is a non-invasive method to study CBF and its variations induced by MAP.

The aim of this study is to test the feasibility of an early-goal directed hemodynamic management with TCD during the first 12 hours after return of spontaneous circulation (ROSC).

Conditions

  • Cardiac Arrest
  • Cerebral Lesion
  • Ischemic Encephalopathy
  • Ischemic Reperfusion Injury

Interventions

OTHER

MAP increased to optimize cerebral blood flow

MAP will be increased to 90-100 mmHg with norepinephrine. If TCD is still abnormal with a MAP of 90-100 mmHg, MAP will be increased to 100-110 mmHg. At each step, all CBF determinants will be recorded as well as cardiac output and Veinous jugular oxygen saturation (SvjO2). When TCD is normalized with no complications, MAP will be maintained at 90-100 or 100-110 mmHg during 24 hours.

OTHER

MAP between 65 and 85 mmHg

MAP will be maintained between 65-85 mmHg, using a norepinephrine infusion as needed.

Sponsors & Collaborators

  • Centre Hospitalier le Mans

    lead OTHER

Principal Investigators

  • Nicolas Chudeau, MD · Centre Hospitalier Le Mans, Intensive Care Unit

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-29
Primary Completion
2023-07-08
Completion
2023-07-08

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04000334 on ClinicalTrials.gov